Published in
Elsevier, Annals of Oncology, 8(27), p. 1585-1593, 2016
Links
- ORCID
- ORCID
- Elsevier
- [hdl.handle.net] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [dash.harvard.edu] | PDF
- [europepmc.org] | PDF
- [dial.uclouvain.be] | PDF
Tools
Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial
Journal article published in 2016 by
P. M. Clement,
T. Gauler,
M. Tahara,
Jean-Pascal H. Machiels,
R. I. Haddad,
J. Fayette,
G. de Castro,
L. F. Licitra 
,
L. de Souza Viana,
E. E. W. Cohen,
J. M. del Campo,
D. Cupissol,
J. J. Grau,
J. B. Vermorken,
J. Guigay
and other authors.
,
L. de Souza Viana,
E. E. W. Cohen,
J. M. del Campo,
D. Cupissol,
J. J. Grau,
J. B. Vermorken,
J. Guigay
and other authors.
This paper is available in a repository.
Full text: Download
Published version:
archiving forbidden
Data provided by 
Abstract
BACKGROUND: In the phase III LUX-Head & Neck 1 (LHN1) trial, afatinib significantly improved progression-free survival (PFS) versus methotrexate in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients progressing on/after platinum-based therapy. This report evaluates afatinib efficacy and safety in prespecified subgroups of patients aged ≥65 and